TECNIOspring PLUS project is ACCIÓ's international talent programme co-financed by the H2020 Marie Skłodowska-Curie actions of the European Union. The aim of the programme is to boosts technology transfer processes by offering R&D companies and centres 2-year employment contracts to host an experienced researcher. The project was granted in May 2019 in order for Nanomol Technologies S.L to contract PhD. Ivana Malvacio as qualified researcher.
The main goal of the project is to develop the potential of the patented DELOS technology platform to produce high quality cosmetic ingredients, based on lipid nanovesicle systems for the delivery of biotechnological actives.
By combining experimental approach with computational simulations, new DELOS nanovesicles for cosmetic applications will be prototyped. The developed systems will be designed to integrate different cosmetic ingredients and active biomolecules for skin and hair applications. The biocompatibility, penetration to the skin and efficacy of the developed active-conjugated DELOS nanovesicles will be tested in-vitro and ex-vivo.
Smart-4-Fabry (S4F) is the acronym of a H2020 funded Project that stands for “Smart functional GLA-nanoformulation for Fabry disease”. Smart-4-Fabry is a collaborative Project funded under the H2020 EU Research and Innovation programme, and started on the 1st January 2017 and will last four years. The S4F Project has been conceived to obtain a new nanoformulation of GLA, that will improve the efficacy and tolerability of this new drug in comparison to the actual treatment for Fabry Disease with non-formulated GLA. In the case of the Fabry Disease (FD), the deficiency of α-Galactosidase A (GLA) enzyme results in the cellular accumulation of neutral glycosphingolipids, leading to widespread vasculopathy with particular detriment to the kidneys, heart and central nervous system. The final benefit expected with S4F project will be seen as considerable reduction on the Fabry disease treatment costs and a substantial improvement in the efficacy of GLA enzyme, together with life-quality of Fabry disease patients. In this Project, Nanomol Technologies is involved in pharmaceutical development of the new reformulated GLA based drug, scale-up of the technology which permits to produce the new nanoformulation, and GMP implementation of a pilot productive line to obtain the new nanoformulation for future clinical testing.
Nanonafres project consist of a multidisciplinary consortium of seven Catalan partners, including public scientific research centres, small companies, primary care centres and public hospitals with the aim to develop a novel pharmaceutical formulation that integrates a marketed free recombinant human Epidermal Growth Factor (rh-EGF) in nanovesicles (NV-rh-EGF) to enable its topical administration and promote wound healing of venous leg ulcers. The Project was granted in October 2016 with a financial programme (RIS3CAT) by the Generalitat of Catalonia (FEDER funds), which is aligned with the European Commission (EC) National/Regional Research and Innovation Strategies for Smart Specialisation (RIS3 strategies). This project is part of the TECSALUT RIS3CAT community coordinated by LEITAT Technology Centre. Nanonafres project is expecting to last for 42 months and will carry out pharmaceutical development of the new nanoformulation required to perform nonclinical testing as well as a clinical study in patients with venous leg ulcers to establish the safety of NV-rh-EGF and obtain an efficacy preliminary proof of concept. Within this framework, Nanomol Technologies is the Leader and Technological Partner of the Nanonafres Project.
The idea of TheraGlio FP7 Cooperation project is to develop a multimodal imaging system for Theranostics (therapy+diagnosis) of patients bearing malignant glioma, the most common primary brain tumour. This technology will avail of new generation Microbubbles (MBs), in which development NANOMOL Technologies is involved, that can simultaneously act as drug delivery system and contrast agent for Magnetic Resonance Imaging, intra-operative Contrast-Enhanced Ultrasound and intra-operative fluorescence microscopic.
The project Nano-Oligomed, started in December 2017, is funded by RISE Marie Curie actions from H2020 and is entitled “Hybrid Nanostructured Oligonucleotide Platforms for Biomedical Applications”. The scientific aim of Nano-OligoMed is the creation of degradable hybrid structures that combine the rigid, inert silica and soft nanovesicle-carriers with the delicate programmable oligonucleotides or artificial oligonucleotide-mimics. The possibility to develop novel oligonucleotide-based materials will enable a) the degradation of the drug carrier at the presence of a specific input as a function of the intrinsic bio-responsive feature of oligonucleotides, b) the activation of a therapeutic function as a result of the bio-molecular interaction between the oligonucleotide-based material and the molecular target (i.e. miRNAs) and c) the delivery of the chemical payload upon cell internalization. With these objectives and in the framework of a public-private consortium, international academic networking, broadening of the research skills and educational activities are supplied to young (PhD students) and senior scientists to enable them acquire specific competences in the field of materials sciences, nanotechnology, molecular biology and molecular medicine.
The main target of this ITN network is the education of a new generation of scientists for the development, via breakthrough research, of two technologically relevant applications, namely two-photon microscopy (2PM) and two-photon polymerization (2PP), with enormous applicative potential in bioimaging, biomedicine, and rapid prototyping techniques. In this ITN, NANOMOL Technologies is involved in the scaling-up of Organic Nanoparticles (ONP) production processes to be used in photonic applications.